Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
POLARITYTE, INC. | Director | Common Stock | 14.4K | $11.4K | $0.79 | Jan 12, 2023 | Direct |
Revance Therapeutics, Inc. | Director | Common Stock | 0 | $0 | $3.65 | Feb 6, 2025 | Direct |
Revance Therapeutics, Inc. | Director | Stock Option (Right to buy) | 23.5K | May 1, 2024 | Direct | ||
ArriVent Biopharma, Inc. | Director | Stock Option (right to buy) | 17.9K | Jan 25, 2024 | Direct | ||
Jasper Therapeutics, Inc. | Director | Stock Option (right to buy) | 7.5K | Jun 6, 2024 | Direct | ||
POLARITYTE, INC. | Director | Stock option (right to buy) | 6.16K | Jan 12, 2023 | Direct |